SCHEMBL66545

SCHEMBL66545

O=C(COc1ccc(F)c(Cl)c1)N1CCC(S(=O)(=O)Nc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
PKM P14618 2/20 0.48
MAPT P10636 3/20 0.47
KDM4E B2RXH2 1/20 0.47
ATF4 P18848 2/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 2/20 0.45
GAA P10253 2/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2B Q13224 1/20 0.44
GPR183 P32249 1/20 0.43
FKBP1A P62942 1/20 0.43
ACLY P53396 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL65663 0.94 ALDH1A1 (0.46) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL8236980 0.89 ALDH1A1 (0.51) ALDH1A1L3MBTL1SMN1; SMN2MAPTKDM4E
SCHEMBL56987 0.87 KMT2A (0.51) ALDH1A1L3MBTL1SMN1; SMN2PKMATF4
SCHEMBL56480 0.86 SMN1; SMN2 (0.53) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL8243869 0.82 SMN1; SMN2 (0.43) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL57050 0.81 KMT2A (0.47) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL65760 0.80 SMN1; SMN2 (0.50) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL8243715 0.78 SMN1; SMN2 (0.41) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL66069 0.77 TDP1 (0.47) ALDH1A1L3MBTL1SMN1; SMN2PKMMAPT
SCHEMBL90762 0.76 GPR183 (0.52) ALDH1A1L3MBTL1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203122-A1 Derivatives for modulation of ion channels TRPV1, TRPA1, TRPV2 ALDH1A1 3010/4885L3MBTL1 4070/4885SMN1; SMN2 672/4885
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS TRPV1, TRPA1, TRPV2 ALDH1A1 3010/4885L3MBTL1 4070/4885SMN1; SMN2 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.